Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Triebel

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Research in Immunology|September 1, 1990
Gamma/delta T cells: from controlled development to functional programsF Triebel
Disease Markers|March 1, 1990
Use of monoclonal antibodies specific for distinct variable or constant regions of the gamma/delta T cell receptor in normal and pathological conditionsF Triebel
La Revue Du Praticien|March 11, 1991
[Interleukin-2 in oncology]F Triebel, T Hercend
La Revue Du Praticien|March 1, 1993
[Cytokines and solid tumors]F Triebel, B Escudier
Progress in Clinical and Biological Research|January 1, 1987
Heterogeneity of cytotoxic lymphocytes potentially relevant for cellular immunotherapy of cancer: implications for designing clinical strategiesF Triebel, T Hercend
Bulletin Du Cancer|January 1, 1988
[Principles of treatment with cells called "LAK" cells]T Hercend, F Triebel
Immunology Today|June 1, 1989
Subpopulations of human peripheral T gamma delta lymphocytesF Triebel, T Hercend
Presse Medicale (Paris, France : 1983)|December 14, 1991
[Human lymphocytes carrying the T gamma/delta receptor]F Triebel, T Hercend
International Immunology|November 5, 1999
The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexesS Hannier, F Triebel
Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2000
A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigensS El Mir, F Triebel
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Research in Immunology|September 1, 1990
Gamma/delta T cells: from controlled development to functional programsF Triebel
Disease Markers|March 1, 1990
Use of monoclonal antibodies specific for distinct variable or constant regions of the gamma/delta T cell receptor in normal and pathological conditionsF Triebel
La Revue Du Praticien|March 11, 1991
[Interleukin-2 in oncology]F Triebel, T Hercend
La Revue Du Praticien|March 1, 1993
[Cytokines and solid tumors]F Triebel, B Escudier
Progress in Clinical and Biological Research|January 1, 1987
Heterogeneity of cytotoxic lymphocytes potentially relevant for cellular immunotherapy of cancer: implications for designing clinical strategiesF Triebel, T Hercend
Bulletin Du Cancer|January 1, 1988
[Principles of treatment with cells called "LAK" cells]T Hercend, F Triebel
Immunology Today|June 1, 1989
Subpopulations of human peripheral T gamma delta lymphocytesF Triebel, T Hercend
Presse Medicale (Paris, France : 1983)|December 14, 1991
[Human lymphocytes carrying the T gamma/delta receptor]F Triebel, T Hercend
International Immunology|November 5, 1999
The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexesS Hannier, F Triebel
Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2000
A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigensS El Mir, F Triebel
Pageof 12